Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Schultz

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|May 7, 2004
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neckJay S Cooper, Thomas F Pajak, Arlene A Forastiere, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2025
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic AstrocytomaJessica L Fleming, Stephanie L Pugh, Susan M Chang, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Oncology|May 6, 2021
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortMaria Vassilakopoulou, Minhee Won, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2019
The transformation of radiation oncology using real-time magnetic resonance guidance: A reviewWilliam A Hall, Eric S Paulson, Uulke A van der Heide, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|May 7, 2004
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neckJay S Cooper, Thomas F Pajak, Arlene A Forastiere, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2025
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic AstrocytomaJessica L Fleming, Stephanie L Pugh, Susan M Chang, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Oncology|May 6, 2021
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortMaria Vassilakopoulou, Minhee Won, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2019
The transformation of radiation oncology using real-time magnetic resonance guidance: A reviewWilliam A Hall, Eric S Paulson, Uulke A van der Heide, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Pageof 7